Cravath, Swaine & Moore has taken the lead for Mylan on its deal for Meda, along with leading Swedish firm Vinge and top Dutch shop NautaDutilh. Cravath previously advised Mylan in 2007 on its $6.6 billion acquisition of Merck KGaA’s worldwide generic drug business.
Mylan only recently gave up on a deal with Perrigo, abandoning a $27 billion hostile bid for its former target in November. Back in August, Mylan agreed to dismiss a conflicts of interest suit it filed against onetime counsel Kirkland & Ellis, which had initially represented Teva in its failed $40 billion takeover attempt of Mylan. (Wilson Sonsini Goodrich & Rosati represented Mylan on that matter, while Gibson, Dunn & Crutcher took the lead for Kirkland.)
This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.
To view this content, please continue to their sites.
Not a Lexis Subscriber?
Subscribe Now
Not a Bloomberg Law Subscriber?
Subscribe Now
LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.
For questions call 1-877-256-2472 or contact us at [email protected]
